BioNTech (BUL:22UA) - Stock Price, News & Analysis

22UA Stock Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

About the company

22UA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 2.1% below our estimate of its fair value

Earnings grew by 37.8% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 38.6% per year for the next 3 years

Shares are highly illiquid

BioNTech SE Competitors

Akeso

SEHK:9926

HK$42.4b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Genmab

CPSE:GMAB

kr.127.4b

Celltrion

KOSE:A068270

₩38.1t

Price History & Performance

Summary of all time highs, changes and price drops for BioNTech
Historical stock prices
Current Share Price	US$121.65
52 Week High	US$140.35
52 Week Low	US$121.65
Beta	0.26
1 Month Change	0%
3 Month Change	-6.57%
1 Year Change	-18.29%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-53.03%

Recent updates

Shareholder Returns

	22UA	BG Biotechs	BG Market
7D	0%	0%	0%
1Y	-18.3%	0%	0%

Return vs Industry: 22UA underperformed the BG Biotechs industry which returned -9.8% over the past year.

Return vs Market: 22UA underperformed the BG Market which returned 10.8% over the past year.

Price Volatility

Is 22UA's price volatile compared to industry and market?
22UA volatility
22UA Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in BG Market	0%
10% least volatile stocks in BG Market	0%

Stable Share Price: 22UA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 22UA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	4,000	Ugur Sahin	www.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.

BioNTech SE Fundamentals Summary

How do BioNTech's earnings and revenue compare to its market cap?
22UA fundamental statistics
Market cap	€32.25b
Earnings (TTM)	€10.32b
Revenue (TTM)	€18.56b

3.1x

P/E Ratio

1.7x

P/S Ratio

Is 22UA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
22UA income statement (TTM)
Revenue	€18.56b
Cost of Revenue	€3.39b
Gross Profit	€15.17b
Other Expenses	€4.85b
Earnings	€10.32b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Mar 27, 2023

Earnings per share (EPS)	42.47
Gross Margin	81.71%
Net Profit Margin	55.60%
Debt/Equity Ratio	0.01%

How did 22UA perform over the long term?

See historical performance and comparison

22UA Stock Overview

Rewards

Risk Analysis

BioNTech SE Competitors

SEHK:9926

HK$42.4b

NasdaqGS:HZNP

US$26.6b

CPSE:GMAB

kr.127.4b

KOSE:A068270

₩38.1t

Price History & Performance

Recent News & Updates

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Recent updates

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

BioNTech SE Provides Revenue Guidance for the Full Year 2023

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age

Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine

BioNTech Reiterates Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: €6.88 (vs €11.42 in 2Q 2021)

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy with Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

Pfizer Inc. and BioNTech SE Submits Variation to the European Medicines Agency

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine Comirnaty for Adolescents 12 Through 15 Years of Age

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Investor sentiment improved over the past week

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

BioNTech SE Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

Pfizer and BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

BioNTech SE Announces Positive Phase 1 Data from MRNA-Based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer Presented At ASCO

BioNTech SE Approves Board Appointments

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose

BioNTech SE and Pfizer Inc. Announces the U.S. Food and Drug Administration Expands Emergency Use Authorization

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission

Now 21% undervalued